PDSB

PDS Biotechnology Corporation (PDSB)

About PDS Biotechnology Corporation (PDSB)

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

Details

Daily high
$1.81
Daily low
$1.63
Price at open
$1.75
52 Week High
$6.68
52 Week Low
$1.53
Market cap
61.7M
Dividend yield
0.00%
Volume
579,082
Avg. volume
398,831
P/E ratio
-1.41

PDS Biotechnology Corporation News

Details

Daily high
$1.81
Daily low
$1.63
Price at open
$1.75
52 Week High
$6.68
52 Week Low
$1.53
Market cap
61.7M
Dividend yield
0.00%
Volume
579,082
Avg. volume
398,831
P/E ratio
-1.41